Blood pressure control remains frustratingly elusive despite decades of pharmaceutical advances, with over half of diagnosed hypertensive patients failing to achieve target readings. This disconnect between available treatments and real-world outcomes has prompted researchers to explore whether the missing link lies not in medication efficacy, but in patient engagement and healthcare delivery models.
The TOGETHER trial across Portugal, Austria, and Spain tests whether community pharmacies can serve as effective hypertension management hubs by combining traditional blood pressure monitoring with vascular age assessment using aortic pulse wave velocity measurements. The cluster-randomized study evaluates whether patients receiving both blood pressure readings and personalized vascular aging data achieve better six-month hypertension control compared to standard pharmacy-based monitoring alone. The intervention creates structured communication pathways between community pharmacists and primary care physicians, with vascular age results shared across both care settings.
This approach addresses a critical gap in cardiovascular prevention: most patients struggle to conceptualize abstract blood pressure numbers, but vascular age provides an intuitive framework linking current readings to long-term health outcomes. Community pharmacies represent an underutilized resource with superior patient access compared to physician offices, yet their role in chronic disease management remains limited. The trial's focus on sustainable pharmacy-physician collaboration could establish scalable models for European healthcare systems facing physician shortages and aging populations. However, the study's observational design limits causal inferences, and the six-month follow-up may insufficient to capture meaningful clinical endpoints like cardiovascular events. Success will likely depend on whether vascular age data genuinely motivates behavioral change or merely adds complexity to already overwhelmed patients.